paclitaxel

P3, N=172, Not yet recruiting, Asan Medical Center | Initiation date: Jun 2025 --> Jan 2026

Epithelial ovarian carcinoma, the deadliest gynecological malignancy, frequently develops treatment resistance through polyploid giant cancer cells (PGCCs) that typically emerge after carboplatin-paclitaxel chemotherapy. Our findings establish that the cytoplasmic SIRT1/β-catenin axis contributes to PGCC stemness, elucidating a novel mechanism underlying chemoresistance. Therefore, targeting cytoplasmic SIRT1 represents a promising therapeutic strategy to overcome PGCC-mediated resistance in this lethal carcinoma.

P3, N=320, Not yet recruiting, Genfleet Therapeutics (Shanghai) Inc.

Combining atezolizumab with bevacizumab and chemotherapy did not significantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum. The safety profile was as expected from previous experience with these drugs.

The combination treatment inhibited PI3K, AKT, and STAT3 expressions, thereby suppressing proliferation and inducing proapoptotic protein expression in HGT-1 cells. Therefore, the combination of MRN and PTX could serve as a therapeutic approach for malignant GC treatment.

P1/2, N=119, Completed, Shanghai Junshi Bioscience Co., Ltd. | Active, not recruiting --> Completed

P3, N=1023, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

Inhibition of LDHAL6A combined with paclitaxel treatment markedly suppresses triple-negative breast cancer growth and metastasis. Collectively, our work not only establishes an advanced model for IVPL but also profiles ultimately exosomal actors in recipient organs for targeted therapy.

P1/2, N=126, Recruiting, Genfleet Therapeutics (Shanghai) Inc.

P1/2, N=110, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Not yet recruiting --> Recruiting | Trial completion date: Mar 2028 --> Dec 2028

Pre-treatment biomarker levels were associated with greater KS tumor burden but not with KS response to chemotherapy + ART in people with advanced AIDS-KS. Differential levels of several serum biomarkers were noted on treatment in progressors and non-progressors, suggesting that increased tumor burden was associated with higher levels of inflammation and immune activation.

The combination of chemotherapy and immune checkpoint blockade therapy shows great potential in tumor treatment, but their integration remains a great challenge. Meanwhile‌, overexpression of programmed cell death ligand 1 (PD-L1) is suppressed by JQ1, thereby reversing PD-L1-mediated immune resistance to synergistically promote adaptive antitumor immune response. This hypoxia-sensitive versatile nanoplatform provides an elegant paradigm for precise tumor therapy.